RP3
Oncolytic virus
Evidence outlook · program status
Discontinued (2023-12), as a strategic decision by the sponsor
Replimune stopped RP3 to focus on its RP1 and RP2 priority studies after CERPASS. The trials below are preserved as the program's evidence history; no evidence signal is assigned to a program the sponsor has stopped.
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. The complete registry, including every study not featured here, is listed below.
| Trial | Phase | Endpoint | Key result | Signal | Source |
|---|---|---|---|---|---|
NCT04735978 NCT04735978 · Solid Tumors Registry: NCT04735978 | 1 | Incidence of dose limiting toxicities (DLTs) during the DLT period (From Day 1 up to 30 days after last dose); Incidence and severity of treatment emergent adverse events (TEAEs) (From Day 1 up to 60 days after last dose); Incidence and severity of serious adverse events (SAEs) (From Day 1 up to 60 days after last dose); Incidence of TEAEs ≥ Grade 3 (From Day 1 up to 60 days after last dose); Percentage of events requiring withdrawal (From Day 1 up to last dose (up to 8 weeks in escalation phase and up to 2 years in combination phase)); Recommended phase 2 dose (RP2D) of RP3 (7 months) 2026-11-30 | In progress: results expected 30 Nov 2026 | not yet graded | link ↗ |
All registered studies
Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.
Phase 2 (2)
What this study did
What this study did
Phase 1 (1)
What this study did
Competitive landscape
Other Tumor cells (oncolytic replication) drugs
Pelareorep. Compare all 2 Tumor cells (oncolytic replication) drugs
1 other tracked programme targets this mechanism, 1 of them ahead of this one.
This drug's own stage for Solid Tumors: Discontinued. Competitors below are sorted furthest-along first.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials | |
|---|---|---|---|---|---|---|
| RP3: this drug | Discontinued | Oncolytic virus | Tumor cells (oncolytic replication) | not yet graded | No reviewed efficacy summary in this indication | |
| Larotrectinib | Approved | Small molecule | TRK (TRKA/TRKB/TRKC, encoded by NTRK1/NTRK2/NTRK3 gene fusions) | Weak signal | No reviewed efficacy summary in this indication | |
| Pembrolizumab | Approved | Monoclonal antibody | PD-1 | not yet graded | No reviewed efficacy summary in this indication | |
| Pembrolizumab Berahyaluronidase Alfa (Keytruda Qlex) | Approved | Monoclonal antibody | PD-1 | not yet graded | No reviewed efficacy summary in this indication | |
| Repotrectinib | Approved | Small molecule | ROS1/NTRK | not yet graded | No reviewed efficacy summary in this indication | |
| Selpercatinib (Retevmo) | Approved | Small molecule | RET | not yet graded | No reviewed efficacy summary in this indication | |
| Pelareorep | Phase 2(overall) | Oncolytic virus | Tumor cells (oncolytic replication) | not yet graded(overall) | No reviewed efficacy summary in this indication | |
| ALG.APV-527 | Phase 1/2 | Multispecific antibody | 4-1BB (CD137) x 5T4 | not yet graded | No reviewed efficacy summary in this indication | |
| CR-001 | Phase 1/2(overall) | Multispecific antibody | PD-1 + VEGF | not yet graded | No reviewed efficacy summary in this indication | |
| EB-SELECT Dual-Target CAR-NK Cells | Phase 1/2 | Cell therapy | Tumor antigen menu (TROP2, MSLN, B7-H3, HER2) | not yet graded | No reviewed efficacy summary in this indication | |
| EB-SELECT Single-Target CAR-NK Cells | Phase 1/2 | Cell therapy | Personalized, biomarker-guided allogeneic chimeric antigen receptor | not yet graded | No reviewed efficacy summary in this indication | |
| Micvotabart Pelidotin | Phase 1/2 | Antibody–drug conjugate | ED-B domain of fibronectin | not yet graded | No reviewed efficacy summary in this indication | |
| Linebacker | —(overall) | Small molecule | PIM kinases (PIM1/2/3) | not yet graded | No reviewed efficacy summary in this indication |
Upcoming events
No upcoming readouts on record for this asset.